The transmembrane proteins contribute to immunodeficiencies induced by HIV-1 and other retroviruses

AIDS

Volumn 28, Issue 8, 2014, Pages 1081-1090

  Denner, Joachim ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

HIV 1; Hyperactivation; Immunosuppression; Immunosuppressive domain; Innate immunity; Microbial translocation; Transmembrane envelope protein

Indexed keywords

VIRUS ENVELOPE PROTEIN; CYTOKINE; MEMBRANE PROTEIN; MUTANT PROTEIN;

CLINICAL FEATURE; ENDOGENOUS RETROVIRUS; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; MOLECULAR MECHANICS; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TUMOR CELL; VIRUS INFECTION; VIRUS REPLICATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY;

CYTOKINES; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE PROTEINS; MUTANT PROTEINS; RETROVIRIDAE; VIRAL ENVELOPE PROTEINS;

EID: 84927565918     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000195     Document Type: Review

References (103)

1. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol 2000; 18:861-926.
2. Lilley BN, Ploegh HL. Viral modulation of antigen presentation: Manipulation of cellular targets in the ER and beyond. Immunol Rev 2005; 207:126-144.
3. Abendroth A, Kinchington PR, Slobedman B. Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol 2010; 342:155-171.
4. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375:411-415.
5. Avota E, Gassert E, Schneider-Schaulies S. Measles virusinduced immunosuppression: from effectors to mechanisms. Med Microbiol Immunol 2010; 199:227-237.
6. Fontana JM, Bankamp B, Rota PA. Inhibition of interferon induction and signaling by paramyxoviruses. Immunol Rev 2008; 225:46-67.
7. Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, van Ommen GJ, et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011; 6:e17848.
8. Glosson NL, Hudson AW. Human herpesvirus-6A and -6B encode viral immunoevasins that downregulate class I MHC molecules. Virology 2007; 365:125-135.
9. Hudson AW, Howley PM, Ploegh HL. A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibility complex class I molecules to lysosomes. J Virol 2001; 75:12347-12358.
10. Ressing ME, van-Leeuwen D, Verreck FA, Keating S, Gomez R, Franken KL, et al. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol 2005; 79:841-852.
11. Ressing ME, van-Leeuwen D, Verreck FA, Gomez R, Heemskerk B, Toebes M, et al. Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A 2003; 100:11583-11588.
12. Tomazin R, Boname J, Hegde NR, Lewinsohn DM, Altschuler Y, Jones TR, et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4R T cells. Nat Med 1999; 5:1039-1043.
13. Biron CA, Su HC, Orange JS. Function and regulation of natural killer (NK) cells during viral infections: characterization of responses in vivo. Methods 1996; 9:379- 393.
14. Meinl E, Fickenscher H, Thome M, Tschopp J, Fleckenstein B. Antiapoptotic strategies of lymphotropic viruses. Immunol Today 1998; 19:474-479.
15. Roulston A, Marcellus RC, Branton PE. Viruses and apoptosis. Annu Rev Microbiol 1999; 53:577-628.
16. Vossen MT, Westerhout EM, Söderberg-Nauclér C, Wiertz EJ. Viral immune evasion: A masterpiece of evolution. Immunogenetics 2002; 54:527-542.
17. Turner PC, Sancho MC, Thoennes SR, Caputo A, Bleackley RC, Moyer RW. Myxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1beta-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virusinfected cells. J Virol 1999; 73:6394-6404.
18. Liu Y, de-Waal Malefyt R, Briere F, Parham C, Bridon JM, Banchereau J, et al. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 1997; 158:604-613.
19. Rode HJ, Janssen W, Rösen-Wolff A, Bugert JJ, Thein P, Becker Y, et al. The genome of equine herpesvirus type 2 harbors an interleukin 10 (IL10)-like gene. Virus Genes 1993; 7:111-206.
20. Dairaghi DJ, Fan RA, McMaster BE, Hanley MR, Schall TJ. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem 1999; 274:21569-21574.
21. Endres MJ, Garlisi CG, Xiao H, Shan L, Hedrick JA. The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8. J Exp Med 1999; 189:1993-1998.
22. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997; 277:1656-1659.
23. Zou P, Isegawa Y, Nakano K, Haque M, Horiguchi Y, Yamanishi K. Human herpesvirus 6 open reading frame U83 encodes a functional chemokine. J Virol 1999; 73:5926-5933.
24. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3:811-821.
25. Rosenberg N, Jolicoeur P. Retroviral pathogenesis in retroviruses. In: Coffin JM, Hughes SH, Varmus HE, editors. Retrovirology Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1997.
26. Wang F, Wang X, Chen H, Liu J, Cheng Z. The critical time of avian leukosis virus subgroup J-mediated immunosuppression during early stage infection in specific pathogen-free chickens. J Vet Sci 2011; 12:235-241.
27. Sonigo P, Barker C, Hunter E, Wain-Hobson S. Nucleotide sequence of Mason-Pfizer monkey virus: An immunosuppressive D-type retrovirus. Cell 1986; 45:375-385.
28. Old LJ, Clarke DA, Benacerraf B, Goldsmith M. The reticuloendothelial system and the neoplastic process. Ann NY Acad Sci 1960; 8:264-280.
29. Hardy WD Jr. Immunopathology induced by the feline leukemia virus. Semin Immunopathol 1982; 5:75-106.
30. Barros N, Woll F, Watanabe L, Montes M. Are increased Foxp3Rregulatory T cells responsible for immunosuppression during HTLV-1 infection? Case reports and review of the literature. BMJ Case Rep 2012; 2012:pii: bcr2012006574. doi: 10.1136/bcr-2012-006574.
31. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A 2010; 107:3782-3787.
32. Levy J. The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. San Diego, London: Academic Press/Elsevier; 1998.
33. Gardner MB, Luciw PA. Animal models of AIDS. FASEB J 1989; 3:2593-2606.
34. Denner J. Immunosuppression by oncogenic retroviridae. In: Zschiesche W. editor. Immune modulation by infectious agents Jena: Fischer Verlag; 1987. pp. 140-201.
35. Hanger JJ, Bromham LD, McKee JJ, O'Brien TM, Robinson WF. The nucleotide sequence of koala (Phascolarctos cinereus) retrovirus: A novel type C endogenous virus related to Gibbon ape leukemia virus. J Virol 2000; 74:4264-4272.
36. Denner J, Young PR. Koala retroviruses: characterization and impact on the life of koalas. Retrovirology 2013; 10:108.
37. Dawood R, Benjelloun F, Pin JJ, Kone A, Chanut B, Jospin F, et al. Generation of HIV- 1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex. AIDS 2013; 27:717-730.
38. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, Louis JM, et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but nonneutralizing antibodies also bind to NHR mimetics. Virology 2008; 377:170-183.
39. Denner J. Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: A comparative study. Hum Vaccin Immunother 2012; 9 (3).
40. Amadori A, Faulkner-Valle GP, De-Rossi A, Zanovello P, Collavo D, Chieco-Bianchi L. HIV-mediated immunosuppression: In vitro inhibition of T-lymphocyte proliferative response by ultraviolet-inactivated virus. Cell Immunol Immunopathol 1988; 46:37-54.
41. Pahwa S, Pahwa R, Saxinger C, Gallo RC, Good RA. Influence of the human T lymphotropic virus/lymphadenopathyassociated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. Proc Natl Acad Sci U S A 1985; 82:8198-8202.
42. Morozov VA, Morozov AV, Semaan M, Denner J. Single mutations in the transmembrane envelope protein abrogate the immunosuppressive property of HIV-1. Retrovirology 2012; 9:67.
43. Hebebrand LC, Mathes LE, Olsen RG. Inhibition of concanavalin A stimulation of feline lymphocytes by inactivated feline leukemia virus. Cancer Res 1979; 37:4532-4533.
44. Denner J, Wunderlich V, Bierwolf D. Suppression of human lymphocyte mitogen response by disrupted primate retroviruses of type C (baboon endogenous virus) and type D (PMFV). Acta Biol Med Germ 1980; 39:K19-K26.
45. Weislow OS. Depression of mitogen-induced lymphocyte blastogenesis by baboon endogenous retrovirus associated components. Proc Soc Exp Biol Med 1981; 166:522- 527.
46. Tacke SJ, Kurth R, Denner J. Porcine endogenous retroviruses inhibit human immune cell function: risk for xenotransplantation? Virology 2000; 268:87-93.
47. Denner J, Wunderlich V, Sydow G. Suppression of human lymphocyte mitogen response by retroviruses of type D. I. Action of highly purified intact and disrupted virus. Arch Virol 1985; 86:177-186.
48. Denner J, Indzhiia L, Wunderlich V, Sydow G, Bierwolf D, Lapin BA. Suppression of human lymphocyte mitogen response by retroviruses of type D. II. Nonactivity of Mason- Pfizer monkey virus versus activity of human cell line derived virus PMFV. Arch Virol 1985; 86:187-196.
49. Morozov VA, Dao Thi L, Denner J. The transmembrane protein of the human endogenous retrovirus-K (HERV-K) modulates cytokine release and gene expression. PLoS One 2013; 8:e7039910.1371/journal.pone.0070399.
50. Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J. Transspecies transmission of the endogenous koala retrovirus. J Virol 2006; 80:5651-5654.
51. Mathes LE, Olsen RG, Hebebrand LC, Hoover EA, Schaller JP, Adams PW, et al. Immunosuppressive properties of a virion polypeptide, a 15, 000-Dalton protein, from feline leukemia virus. Cancer Res 1979; 39:950-955.
52. Denner J, Wunderlich V, Bierwolf D. Suppression of human lymphocyte mitogen response by proteins of the type-D retrovirus PMFV. Int J Cancer 1986; 37:311-316.
53. Cianciolo GJ, Matthews TJ, Bolognesi DP, Snyderman R. Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses. J Immunol 1980; 124:2900-2905.
54. Oostendorp RA, Meijer CJ, Scheper RJ. Immunosuppression by retroviral-envelope-related proteins, and their role in nonretroviral disease. Crit Rev Oncol Hematol 1993; 14:189-206.
55. Denner J. Immunosuppression by retroviruses: Implications for xenotransplantation. Ann NY Acad Sci 1998; 862:75- 86.
56. Olsen RG, Hoover EA, Schaller JP, Mathes LE, Wolff LH. Abrogation of resistance to feline oncornavirus disease by immunization with killed feline leukemia virus. Cancer Res 1977; 37:2082-2085.
57. Wood GW. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus. Cancer Res 1976; 36:4552-4557.
58. Mangeney M, Heidmann T. Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc Natl Acad Sci USA 1998; 95:14920-14925.
59. Blaise S, Mangeney M, Heidmann T. The envelope of Mason- Pfizer monkey virus has immunosuppressive properties. J Gen Virol 2001; 82:1597-1600.
60. Mangeney M, de-Parseval N, Thomas G, Heidmann T. The fulllength envelope of an HERV-H human endogenous retrovirus has immunosuppressive properties. J Gen Virol 2001; 82:2515-2518.
61. Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, Letzelter C, et al. Placental syncytins: genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc Natl Acad Sci USA 2007; 104:20534-20539.
62. Koutsonikolis A, Haraguchi S, Brigino EN, Owens UE, Good RA, Day NK. HIV-1 recombinant gp41 induces IL-10 expression and production in peripheral blood monocytes but not in T lymphocytes. Immunol Lett 1997; 55:109-113.
63. Takeshita S, Breen EC, Ivashchenko M, Nishanian PG, Kishimoto T, Vredevoe DL, et al. Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocyte cell line. Cell Immunol 1995; 165:234-242.
64. Speth C, Joebstl B, Barcova M, Dierich MP. HIV-1 envelope protein gp41 modulates expression of interleukin-10 and chemokine receptors on monocytes, astrocytes and neurones. AIDS 2000; 14:629-636.
65. Barcova M, Kacani L, Speth C, Dierich MP. Gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production. J Infect Dis 1998; 177:905-913.
66. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006; 80:2515-2528.
67. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985; 230:453-455.
68. Haraguchi S, Good RA, Day-Good NK. A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways. Immunol Res 2008; 41:46-55.
69. Cianciolo GJ, Bogerd H, Snyderman R. Human retrovirusrelated peptides inhibit T-lymphocyte proliferation. Immunol Lett 1988; 19:7-14.
70. Ruegg CL, Monell CR, Strand M. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1. J Virol 1989; 63:3257-3260.
71. Denner J, Norley S, Kurth R. The immunosuppressive peptide of HIV-1: functional domains and immune response in AIDS patients. AIDS 1994; 8:1063-1072.
72. Denner J, Persin C, Vogel T, Haustein D, Norley S, Kurth R. The immunosuppressive peptide of HIV-1 inhibits T- And B-lymphocyte reactivities in vitro. J AIDS Hum Retrovirol 1996; 12:442-450.
73. Fausther-Bovendo H, Vieillard V, Sagan S, Bismuth G, Debré P. HIV gp41 engages gC1qR on CD4R T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog 2010; 1:e1000975.
74. Vieillard V, Crouzet J, Boufassa F, Sennepin A, Fang HT, Debré P, Meyer L. Specific anti-gp41 antibodies predict HIV-1 disease progression. J Acquir Immune Defic Syndr 2012; 61:403- 405.
75. Vieillard V, Dereuddre-Bosquet N, Mangeot-Méderlé I, Le Grand R, Debré P. An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques. Vaccine 2012; 30:6883-6891.
76. Monell CR, Strand M. Structural and functional similarities between synthetic HIV gp41 peptides and defensins. Clin Immunol Immunopathol 1994; 71:315-324.
77. Schlecht-Louf G, Mangeney M, El-Garch H, Lacombe V, Poulet H, Heidmann T. A targeted mutation within the FeLV envelope protein immunosuppressive domain to improve a canarypox-based FeLV vaccine. J Virol 2013; 88:992-1001.
78. Denner J, Eschricht M, Lauck M, Semaan M, Schlaermann P, Ryu H, et al. Modulation of cytokine release and gene expression by the immunosuppressive domain of gp41 of HIV-1. PLoS One 2013; 8:e55199.
79. Qureshi NM, Coy DH, Garry RF, Henderson LA. Characterisation of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. AIDS 1990; 4:553-558.
80. Denner J, Vogel T, Norley S, Hoffmann A, Kurth R. The immunosuppressive (ISU-) peptide of HIV-1: binding proteins on lymphocyte detected by different methods. J Cancer Res Clin Oncol 1995; 121 (Suppl 1):35.
81. Chen YH, Ebenbichler C, Vornhagen R, Schulz TF, Steindl F, Böck G, et al. HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. AIDS 1992; 6:533-539.
82. Ebenbichler CF, Röder C, Vornhagen R, Ratner L, Dierich MP. Cell surface proteins binding to recombinant soluble HIV-1 and HIV-2 transmembrane proteins. AIDS 1993; 7:489-495.
83. Chen YH, Speth C, Wu W, Stockl G, Xiao Y, Yu T, et al. Antigenic characterisation of HIV-1 gp41 binding proteins. Immunol Lett 1998; 62:75-79.
84. Kizaki T, Mitani M, Cianciolo GJ, Ogasawara M, Good RA, Day NK. Specific association of retroviral envelope protein, p15E, with human cell surfaces. Immunol Lett 1991; 28:11- 18.
85. Henderson LA, Qureshi MN. A peptide inhibitor of human immunodeficiency virus infection binds to novel cell surface polypeptides. J Biol Chem 1993; 268:16291-16297.
86. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010; 8:55-67.
87. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4R T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
88. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21:6-13.
89. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012; 122:1712-1716.
90. Estes JD. Enhancing immune responses to limit chronic immune activation during SIV. J Clin Invest 2012; 122:1611-1614.
91. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Reevaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One 2013; 8:e60186.
92. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Natural SIV hosts: Showing AIDS the door. Science 2012; 335:1188-1193.
93. Li B, Stefano-Cole K, Kuhrt DM, Gordon SN, Else JG, Mulenga J, et al. Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies. J Virol 2010; 12:6248- 6253.
94. Zahn RC, Rett MD, Li M, Tang H, Korioth-Schmitz B, Balachandran H, et al. Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. Blood 2010; 115:3070-3078.
95. Beer BE, Brown CR, Whitted S, Goldstein S, Goeken R, Plishka R, et al. Immunodeficiency in the absence of high viral load in pig-tailed macaques infected with Simian immunodeficiency virus SIVsun or SIVlhoest. J Virol 2005; 79:14044-14056.
96. Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 2005; 102:14807-14812.
97. Denner J. Endogenous retroviruses. In: Kurth R, Bannert N, editors. Retroviruses: Molecular biology, genomics and pathogenesis Caister Academic Press; 2010: pp. 35-69.
98. Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, et al. An endogenous retrovirus derived from human melanoma cells. Cancer Res 2003; 63:8735-8741.
99. Büscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 2005; 65:4172-4180.
100. Büscher K, Hahn S, Hofmann M, Trefzer U, Ozel M, Sterry W, et al. Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res 2006; 16:223- 234.
101. Kämmerer U, Germeyer A, Stengel S, Kapp M, Denner J. Human endogenous retrovirus K (HERV-K) is expressed in villous and extravillous cytotrophoblast cells of the human placenta. J Reprod Immunol 2011; 91:1-8.
102. Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000; 403:785-789.
103. Venables PJ, Brookes SM, Griffiths D, Weiss RA, Boyd MT. Abundance of an endogenous retroviral envelope protein in placental trophoblasts suggests a biological function. Virology 1995; 211:589-592.